Recombinant expression vector, recombinant cell, application of recombinant cell and exogenous active substance biosynthesis method
By developing recombinant expression vectors and RtGGA Assembly Platform in yeast yeast, the problem of insufficient genetic editing and metabolic engineering transformation tools was solved, and an efficient synthetic biology platform was established, which promoted its biomanufacturing and biology in biomanufacturing. It has been applied in the pharmaceutical field and has achieved efficient biosynthesis of various exogenous active substances such as nervous acid.
Patent Information
- Application Number
- CN202411019416.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-29
- Publication Date
- 2024-11-08
AI Technical Summary
The imperfect tools of the Roundus yeast in genetic editing and metabolic engineering transformation hinder its progress in the field of synthetic biology, and the lack of effective gene editing tools and synthetic biology platforms limits its exogenous sources such as nervous acids. Application of active substance production.
A recombinant expression vector and recombinant cell system has been developed, including basic vectors, promoters, exogenous genes, terminators and screening marker genes. The RtGGA Assembly Platform is used to randomly integrate and express multiple genes to establish efficient, flexible, standardized, Modular synthetic biology platform.
The integration and expression process of multiple genes in yeast rosporeus simplifies the process, promotes its application in the fields of biomanufacturing, bioenergy and biomedicine, and realizes the efficient biosynthesis of various exogenous active substances such as nerucic acid.
Smart Images

Figure CN118910117A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of synthetic biology, and in particular to a recombinant expression vector, a recombinant cell and applications thereof, and a method for biosynthesizing an exogenous active substance. Background Art
[0002] Rhodotorula toruloides is a non-model yeast that can naturally synthesize a variety of carotenoids and oils. It can naturally synthesize important compounds such as carotenoids, oils, phenylalanine ammonia lyase and d-amino acid oxidase, and can accumulate oils that exceed 70% of its own cell dry weight. This strain has the characteristics of high-density fermentation and can tolerate low pH values, high osmotic stress, oxidative stress, etc. In particular, the yeast can efficiently utilize various lignocellulose hydrolysates as carbon sources and has strong tolerance and metabolic capacity for hydrolysate by-products. Rhodotorula toruloides has been reported to be used in the production research of microbial oils, terpene compounds, various high-value enzymes, sugar alcohols and polyketide compounds, and has broad industrial application prospects.
[0003] At present, the genetic editing and metabolic engineering tools for Rhodosporidium toroculans are not yet perfect. It cannot perform precise gene editing and multiple rounds of iterative integration like model organisms such as Yarrowia lipolytica or Saccharomyces cerevisiae, which hinders its progress in synthetic biology. Its natural metabolic characteristics have not been fully developed and utilized, and there is still much room for improvement in the production of high-value natural products. In order to perform convenient genetic operations in this yeast, it is necessary to develop a more efficient gene expression platform.
[0004] Golden Gate cloning technology relies on Type IIS restriction endonucleases, which were first discovered in 1996. Type IIS restriction endonucleases differ from "traditional" restriction endonucleases in that they cut outside of the recognition sequence, forming sticky ends of 4 bases. Since these sticky ends are not part of the recognition sequence, they can be customized to directly assemble DNA fragments. This technology can precisely insert target gene fragments into vectors, or combine multiple gene fragments together to form complex gene structures. In the field of synthetic biology, Golden Gate cloning technology can be used to construct complex gene networks and metabolic pathways. By connecting multiple gene fragments, synthetic biology systems with specific functions can be created. This technology has been widely used in model organisms such as Yarrowia lipolytica and Saccharomyces cerevisiae to study biological processes and produce useful biological products, but it has not been reported in Rhodosporidium toruloides.
[0005] Nervonic acid (C24:1) is a very long chain monounsaturated fatty acid containing 24 carbon atoms. It is an important component of nerve cell membranes, can promote the development of the nervous system, has a therapeutic effect on various demyelinating diseases, and can also be used to enhance the body's immune function, fight cancer, and fight AIDS. Nervonic acid can be extracted from animals, plants, and microorganisms, or obtained through chemical synthesis. At present, my country mainly obtains it by extracting it from plants such as Acer truncatum, Xanthoceras sorbifolia, and Xanthoceras glutinosae. However, due to the narrow distribution, low yield, and long cycle of these woody plants, nervonic acid is still scarce and expensive.
[0006] With the development of synthetic biology, genetically engineered yeast has become one of the emerging possible sources of neuraminic acid, which may be able to supplement or even replace the traditional plant neuraminic acid sources. Due to its special fatty acid composition, metabolic characteristics and robustness, Rhodosporidium toruloides is a potential chassis strain that can be used to develop and produce various compounds including but not limited to neuraminic acid. However, due to the lack of effective gene editing tools and synthetic biology platforms, there are still few studies on the genetic manipulation and utilization of Rhodosporidium toruloides. Therefore, there is an urgent need to develop a fast, efficient, standardized and modular synthetic biology platform to promote the application of Rhodosporidium toruloides in the production of exogenous active substances such as neuraminic acid.
[0007] In view of this, the present invention is proposed. Summary of the invention
[0008] The purpose of the present invention is to provide a recombinant expression vector, a recombinant cell and its application and a method for biosynthesis of exogenous active substances to simplify and accelerate the integration and expression process of multiple genes in Rhodosporidium toruloides, thereby establishing an efficient, flexible, standardized and modular synthetic biology platform, promoting the development of the field of synthetic biology of Rhodosporidium toruloides, and promoting the wide application of Rhodosporidium toruloides in the fields of biomanufacturing, bioenergy and biomedicine. In addition, the recombinant expression vector provided by the present invention can be used for the biosynthesis of various exogenous active substances such as nervonic acid, and has a wide spectrum of application value.
[0009] The present invention is achieved in that:
[0010] In a first aspect, the present invention provides a recombinant expression vector, which includes a basic vector and the following elements on the basic vector: a promoter, a foreign gene, a terminator and a selection marker gene; the promoter is an endogenous constitutive promoter in Rhodosporidium toruloides;
[0011] The basic vector also includes a pZPK skeleton, a bacterial selection marker expression cassette and a fungal selection marker expression cassette; and there are at least two foreign genes.
[0012] In a second aspect, the present invention provides a recombinant cell or a recombinant bacterium, which comprises the above-mentioned recombinant expression vector.
[0013] In a third aspect, the present invention also provides a Rhodosporidium toruloides cell capable of biosynthesizing exogenous active substances, which comprises the above-mentioned recombinant expression vector.
[0014] In a fourth aspect, the present invention also provides the use of a recombinant expression vector, a recombinant cell or a recombinant bacterium or a chassis Rhodosporidium toruloides cell in the synthesis of exogenous active substances.
[0015] In a fifth aspect, the present invention further provides a method for biosynthesis of an exogenous active substance, which comprises any one of the following methods (1)-(2):
[0016] (1) transforming host cells with the recombinant expression vector and culturing the cells;
[0017] (2) culturing recombinant cells or recombinant bacteria or Rhodosporidium toruloides cells;
[0018] Preferably, in the method (1), the recombinant expression vector is first transformed into Agrobacterium; and then the Agrobacterium is transformed into Rhodosporidium toruloides;
[0019] Preferably, the recombinant expression vector is first transformed into Escherichia coli, and the recombinant expression vector with correct sequencing is selected to transform Agrobacterium; and then the Agrobacterium is transformed into Rhodosporidium toruloides.
[0020] The present invention has the following beneficial effects:
[0021] The present invention has developed a new genetic transformation operation tool (named RtGGA Assembly Platform), which includes a promoter, a terminator, a screening marker gene and a basic vector; it can realize the random integration and expression of multiple genes at one time, and can perform multiple rounds of gene expression integration. The establishment of RtGGA Assembly Platform simplifies the integration and expression process of multiple genes in Rhodosporidium toruloides, and establishes an efficient, flexible, standardized and modular Rhodosporidium toruloides synthetic biology platform.
[0022] The invention is expected to promote the development of synthetic biology of Rhodosporidium toruloides and promote the widespread application of Rhodosporidium toruloides in biomanufacturing, bioenergy, biomedicine and other fields.
[0023] In addition, the recombinant expression vector provided by the present invention can be used for the biosynthesis of various exogenous active substances such as neuraminic acid, and has a wide spectrum of application value. The biosynthesis method of the exogenous active substance provided by the present invention is simple and easy to implement, and is convenient for industrial production. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.
[0025] Figure 1 The components and schematic diagram of the RtGGA Assembly Platform;
[0026] Figure 2 The colony PCR results of the intermediate vector carrying elements such as promoter 1 / 2 / 3, terminator 1 / 2 / 3, and selection marker;
[0027] Figure 3 This is the colony PCR result of the final vector of pZPK-Ampr-Kanr-RFP;
[0028] Figure 4 The figure is the result of electrophoresis of restriction enzyme digestion of the final vector with restriction enzyme BsaI;
[0029] Figure 5 This is the colony PCR result of the recombinant expression vector (RtGGA-3KCS vector);
[0030] Figure 6 Colony PCR results for Agrobacterium single clone;
[0031] Figure 7 This is a diagram showing the detection results of three exogenous genes in the recombinant Rhodosporidium toruloides;
[0032] Figure 8 The gas chromatography detection results of the recombinant NP11 strain and the NP11 strain without 3KCS integration are shown;
[0033] Fig. 9 Vector map of the basic vector pZPK-AmpR-KanR-RFP. DETAILED DESCRIPTION
[0034] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.
[0035] The term "expression vector" refers to bacterial plasmids, yeast plasmids or other vectors well known in the art. Any plasmid or vector can be used as long as it can replicate and be stable in the host. An important feature of an expression vector is that it usually contains a replication origin, a promoter, a marker gene and a translation control element.
[0036] The "Rhodosporidium toruloides" in the present invention includes any diploid and haploid, wild-type strain and auxotrophic strain belonging to the "species".
[0037] The "exogenous gene" of the present invention includes protein coding sequences, antisense RNA coding sequences and nuclease coding sequences that can be expressed in bacteria or fungi (such as red winter spore yeast) strains. Among them, examples of protein coding sequences that can be expressed in red winter spore yeast strains include proteins or nucleic acid sequences derived from such genus, and are not limited thereto, and also include proteins or nucleic acid sequences derived from other microorganisms, plants and animals. It should be understood that when using protein coding sequences derived from other microorganisms, plants and animals as target genes (i.e., exogenous genes or exogenous target genes), in order to optimize the expression in red winter spore yeast strains, it is usually necessary to codon optimize the exogenous gene for the codon priority of the red winter spore yeast strain. And codon optimization belongs to the conventional technical means in this area. When expressing exogenous genes in the genus Saccharomyces, Sporebola and Rhodotorula strains, it is also necessary to codon optimize the exogenous genes.
[0038] In this article, "promoter" refers to a DNA sequence that can be recognized and bound by RNA polymerase and can initiate gene transcription. The term "promoter" can also be understood to include: 5' non-coding region, cis-acting elements (such as enhancers) and other nucleotide sequences that can bind to transcription factors.
[0039] The presence or strength of a promoter is usually indicated by promoter activity, which is determined by connecting a reporter gene (such as a resistance gene) downstream of the promoter, transforming the DNA construct into a corresponding host cell, and detecting whether the reporter gene is expressed. If expression of the reporter gene connected downstream of the promoter is observed, the promoter is considered to be active in the host cell into which it is transformed.
[0040] In this article, "terminator" refers to a DNA sequence on the chromosome that provides a termination signal to separate RNA polymerase from the DNA template and terminate transcription. The activity of the terminator can be determined by effectively expressing the reporter gene through a "promoter-reporter gene-terminator" construct.
[0041] In a first aspect, the present invention provides a recombinant expression vector, which includes a basic vector and the following elements on the basic vector: a promoter, a foreign gene, a terminator and a selection marker gene; the promoter is an endogenous constitutive promoter in Rhodosporidium toruloides;
[0042] The basic vector also includes a pZPK skeleton, a bacterial selection marker expression cassette and a fungal selection marker expression cassette; and there are at least two foreign genes.
[0043] The inventors found that the above-mentioned recombinant expression vector can realize the random integration and expression of multiple genes at one time, and can perform multiple rounds of gene expression integration. The establishment of the RtGGA Assembly Platform simplifies the integration and expression process of multiple genes in Rhodosporidium toruloides, and establishes an efficient, flexible, standardized and modular Rhodosporidium toruloides synthetic biology platform.
[0044] In a preferred embodiment of the present invention, the vector is a bacterial vector or a fungal vector.
[0045] Transformation of host cells with vectors can be carried out using conventional techniques well known to those skilled in the art. When the host is a prokaryotic organism such as Escherichia coli, competent cells capable of absorbing DNA can be harvested after the exponential growth phase and treated with CaCl 2 Another method is to use MgCl 2 In addition, the Agrobacterium transformation method can also be used. If necessary, the transformation can also be carried out by electroporation. When the host is a eukaryotic organism, the following DNA transfection methods can be used: calcium phosphate coprecipitation method, conventional mechanical methods such as microinjection, electroporation, liposome packaging, etc.
[0046] The obtained transformant can be cultured by conventional methods to express the polypeptide encoded by the gene of the present invention. Depending on the host cell used, the culture medium used in the culture can be selected from various conventional culture media. Culture is carried out under conditions suitable for the growth of the host cells. After the host cells grow to an appropriate cell density, the selected promoter is induced by a suitable method (such as temperature conversion or chemical induction), and the cells are cultured for a period of time.
[0047] In addition, the expression vectors preferably contain one or more selectable marker genes to provide a phenotypic trait for selection of transformed host cells, such as tetracycline or ampicillin resistance for E. coli.
[0048] In a preferred embodiment of the present invention, the vector comprises an expression control element operably linked to the exogenous gene; the expression control element is a promoter, a terminator and / or an enhancer.
[0049] Suitable promoter sequences for yeast host cells include promoters for glycolytic enzymes, such as triosephosphate isomerase (TPI), phosphoglycerate kinase (PGK), glyceraldehyde-3-phosphate dehydrogenase (GAPDH or GAP) and variants thereof, lactase (LAC) and galactosidase (GAL), Pichia pastoris glucose-6-phosphate isomerase promoter (PPGI), 3-phosphoglycerate kinase promoter (PPGK), glyceraldehyde phosphate dehydrogenase promoter (pGAP), translation elongation factor promoter (PTEF) and Pichia pastoris enolase 1 (PEN01), triosephosphate isomerase (PTPI), ribosomal subunit proteins (PRPS2, PRPS7, PRPS31, PRPL1), alcohol oxidase promoters (PAOX1, PAOX2), and oligosaccharide phosphodiesterase (DPS). or variants with modified characteristics, formaldehyde dehydrogenase promoter (PFLD), isocitrate lyase promoter (PICL), α-ketoisocaproate decarboxylase promoter (PTHI), heat shock protein family members (PSSA1, PHSP90, PKAR2), 6-phosphogluconate dehydrogenase (PGND1), phosphoglycerate mutase (PGPM1), transketolase (PTKL1), phosphatidylinositol synthase (PPIS1), iron-02-oxidoreductase (PFET3), high affinity iron permease (PFTR1), repressible alkaline phosphatase (PPH08), N-myristoyl transferase (PNMT1), pheromone response transcription factor (PMCM1), ubiquitin (PUBI4), single-stranded DNA endonuclease (PRAD2) promoter.
[0050] Other examples of suitable promoters include Saccharomyces cerevisiae enolase (ENO-1), Saccharomyces cerevisiae galactokinase (GAL1), Saccharomyces cerevisiae alcohol dehydrogenase / glyceraldehyde-3-phosphate dehydrogenase (ADH1, ADH2 / GAP), Saccharomyces cerevisiae phosphate (TPI), Saccharomyces cerevisiae metallothionein (CUP1), and Saccharomyces cerevisiae 3-phosphoglycerate kinase (PGK), and the maltase gene promoter (MAL).
[0051] In a preferred embodiment of the present invention, the endogenous constitutive promoter in Rhodosporidium toruloides is selected from at least one of a glucose 6-phosphate isomerase promoter (PPGI), a 3-phosphoglyceraldehyde dehydrogenase promoter (pGPD), a fructose 1,6-bisphosphate aldolase promoter (pFBA), a glyceraldehyde phosphate dehydrogenase promoter, a translation elongation factor promoter, and a promoter of Pichia pastoris enolase 1, a triose phosphate isomerase, a ribosomal subunit protein, an alcohol oxidase promoter or a variant with modified characteristics, a formaldehyde dehydrogenase promoter, an isocitrate lyase promoter, an α-ketoisocaproate decarboxylase promoter, a heat shock protein family member promoter, a 6-phosphogluconate dehydrogenase promoter, a phosphoglycerate mutant enzyme promoter, a transketolase promoter, and a phosphatidylinositol synthase promoter.
[0052] In a preferred embodiment of the present invention, the endogenous constitutive promoter in Rhodosporidium toruloides is selected from at least one of a glucose 6-phosphate isomerase promoter, a 3-phosphoglyceraldehyde dehydrogenase promoter, and a fructose 1,6-bisphosphate aldolase promoter;
[0053] In a preferred embodiment of the present invention, the nucleotide sequences of the glucose 6-phosphate isomerase promoter, the glyceraldehyde-3-phosphate dehydrogenase promoter and the fructose 1,6-bisphosphate aldolase promoter are shown in SEQ ID NOs: 1-3, respectively.
[0054] In a preferred embodiment of the present invention, the exogenous gene is selected from genes used to express exogenous peptides or exogenous proteins.
[0055] In a preferred embodiment of the present invention, the exogenous peptide or exogenous protein is selected from enzymes in fatty acid synthesis, enzymes in exogenous terpenoid synthesis, enzymes in sugar alcohol synthesis and enzymes in polyketide synthesis.
[0056] In a preferred embodiment of the present invention, the fatty acid is selected from the group consisting of long-chain polyunsaturated fatty acids, long-chain monounsaturated fatty acids, long-chain saturated fatty acids, medium-chain fatty acids and short-chain fatty acids;
[0057] The long-chain polyunsaturated fatty acids are selected from one or more of the following: eicosapentaenoic acid (EPA, C20:5n3), α-linolenic acid (ALA, C18:3n3), γ-linolenic acid (C18:3n6), linoleic acid (C18:2n6, allcis), linolenic acid (C18:2n6, alltrans), conjugated linoleic acid (CLA, C18:2), myristoleic acid, 10,13-nonadecacyclopentaenoic acid (C18:2n6, allcis), linolenic acid (C18:2n6, alltrans), conjugated linoleic acid (CLA, C18:2), myristoleic acid, 10,13-nonadecacyclopentaenoic acid (C18:2n6, allcis), linolenic acid (C18:2n6, alltrans), linolenic acid (C18:2n6, alltrans), linolenic acid (C18:2n6, alltrans), linolenic acid (C18:2n6, allcis ...cis), linolenic acid (C18:2n6, allcis), linolenic acid (C18:2n6, allci Acid, cis-11,14,17-eicosatrienoic acid (C20:3n3), cis-8,11,14-eicosatrienoic acid methyl ester (C20:3n6), arachidonic acid (C20:4n6), 13Z,16Z-docosadienoic acid (C22:2n6), docosatetraenoic acid (C22:4n6), docosapentaenoic acid (C22:5n6) and docosahexaenoic acid (DHA, C22:6n3).
[0058] The long-chain monounsaturated fatty acids are selected from one or more of the following: palmitate, palmitoleic acid, 10E-heptadecenoic acid (C17:1n7, trans), 10Z-heptadecenoic acid (C17:1n7, cis), elaidic acid, octadecenoic acid, ricinoleic acid, oleic acid (C18:1n9), nonadecenoic acid (cis-10), 11Z-eicosenoic acid and erucic acid; preferably 11Z-eicosenoic acid, oleic acid (C18:1n9), elaidic acid, octadecenoic acid, 10E-heptadecenoic acid (C17:1n7, trans), 10Z-heptadecenoic acid (C17:1n7, cis) or a combination thereof;
[0059] The long-chain saturated fatty acids are selected from one or more of the following: myristic acid, palmitic acid, margaric acid, 12-hydroxystearic acid, stearic acid, eicosanoic acid / arachidic acid, heneicosanoic acid, docosanoic acid and tetracosanoic acid; preferably 12-hydroxystearic acid, stearic acid and palmitic acid or a combination thereof; the medium-chain fatty acids are selected from one or more of the following: suberic acid and azelaic acid; or the short-chain fatty acids are selected from one or more of the following: acetic acid, propionic acid, isobutyric acid, butyric acid, isovaleric acid, valeric acid, caproic acid, 2-hydroxycaproic acid and 2-hydroxy-3-methylbutyric acid.
[0060] The long-chain monounsaturated fatty acid is selected from palmitate, palmitoleic acid, 10E-heptadecenoic acid (C17:1n7, trans), 10Z-heptadecenoic acid (C17:1n7, cis), elaidic acid, octadecenoic acid, ricinoleic acid, oleic acid (C18:1n9), nonadecenoic acid (cis-10), 11Z-eicosenoic acid, erucic acid and C24 monounsaturated fatty acids;
[0061] In a preferred embodiment of the present invention, the C24 monounsaturated fatty acid is nervonic acid.
[0062] In an optional embodiment, the exogenous terpenoid compound is selected from monoterpenes and their derivatives, sesquiterpenes and their derivatives, diterpenes and their derivatives, diterpenes and their derivatives, triterpenes and their derivatives, tetraterpenes and their derivatives, or polyterpenoid compounds. The chassis cell or strain provided by the present invention is widely applicable to the synthesis of exogenous terpenoid compounds, and has the advantages of wide application range and universal applicability.
[0063] In an alternative embodiment, the diterpene is selected from ophiobolin F; in an alternative embodiment, the diterpene is selected from taxadiene.
[0064] In an optional embodiment, the exogenous terpenoid compounds include but are not limited to nerol, geranyl, 1,8-terpenoids, menthol, menthone, α-pinene, borneol, camphor, abietadiene, amorphadiene, carene, α-farnesene, β-farnesene, farnesol, geraniol, geranylgeraniol, linalool, limonene, myrcene, nerolidol, ocimene, patchouli alcohol, β-pinene, terpinene, γ-terpinene, terpinene, valencene, vitamin A, ambroxan, squalene, β-carotene, artemisinin, lycopene or astaxanthin.
[0065] The sugar alcohol compound includes any one selected from erythritol, threitol, arabinitol, xylitol, ribitol, iditol, galactitol, sorbitol, mannitol, volemitol, perseitol, octitol, inositol, and quercitol.
[0066] The polyketide compounds include olivetol, olive acid, divalinol, divalinol acid, lichenol, moss acid, cinnamoyl alkane polyketide compounds and the like.
[0067] In a preferred embodiment of the present invention, the enzyme used in fatty acid synthesis is selected from 3-ketoacyl-CoA synthetase.
[0068] In a preferred embodiment of the present invention, the exogenous gene is selected from at least one of CgKCS of Cardamine graeca, AtKCS18 of Arabidopsis thaliana and CraKCS of Crambe abyssinica;
[0069] In a preferred embodiment of the present invention, the nucleotide sequences of CgKCS, AtKCS18 and CraKCS are shown in SEQ ID NOs: 4-6.
[0070] In a preferred embodiment of the present invention, the terminator is selected from at least one of the terminator nosT of the nopaline synthase gene of Agrobacterium tumefaciens, the terminator T35S of CaMV35S, the endogenous heat shock protein Thsp of Rhodosporidium toruloides, and the endogenous 3-phosphoglyceraldehyde dehydrogenase Tgpd of Rhodosporidium toruloides;
[0071] In a preferred embodiment of the present invention, the nucleotide sequences of CaMV35S terminator T35S, Rhodosporidium toruloides endogenous heat shock protein Thsp and Rhodosporidium toruloides endogenous 3-phosphoglyceraldehyde dehydrogenase Tgpd are shown in SEQ ID NOs: 7-9, respectively;
[0072] In a preferred embodiment of the present invention, when there are multiple foreign genes, the elements on the basic vector include: promoter-foreign gene 1-terminator-promoter-foreign gene 2-terminator-...foreign gene n-terminator-selection marker gene;
[0073] Or, screening marker gene-promoter-foreign gene 1-terminator-promoter-foreign gene 2-terminator-...foreign gene n-terminator; n≥2. n is, for example, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 or 19.
[0074] In the preferred embodiment of the present invention, the selection marker gene is selected from at least one of bleomycin, geneticin, hygromycin, nourseoin, xanthine / guanine phosphotransferase gene (gpt), hypoxanthine phosphotransferase gene (Hprt), thymidine kinase gene (tk), puromycin acetyltransferase gene (puro), and auxotrophic marker gene. In other embodiments, it can also be other antibiotic resistance genes.
[0075] The auxotrophic marker gene is selected from at least one of URA3 gene, LEU2 gene, TRP3 gene, HIS4 gene, ADE11 gene, LYS gene, argB gene, trpC gene, pyrG gene, or met3 gene. If the auxotrophic marker gene is selected from marker genes such as URA3, LEU2, TRP3, HIS4, ADE11, LYS, etc., the host bacteria with corresponding gene deletion can only grow in a complete medium, but cannot grow in a basic medium lacking corresponding nutrients, and the vector DNA with the selection marker is integrated with the host chromosome, so that the host bacteria can grow in a selective medium.
[0076] In a preferred embodiment of the present invention, the bacterial selection marker expression cassette is selected from AmpR expression cassette, KanR expression cassette, tetracycline resistance gene (tetR) expression cassette, spectinomycin resistance gene expression cassette, chloramphenicol resistance gene (cat) expression cassette, RFP expression cassette and hygromycin resistance gene (hpt), and the fungal selection marker expression cassette is selected from resistance selection marker expression cassette and / or nutritional deficiency marker expression cassette; the resistance selection marker expression cassette is selected from: geneticin resistance gene expression cassette, bleomycin resistance gene expression cassette, nourseointegratin resistance gene expression cassette or hygromycin resistance gene (hpt); the nutritional deficiency marker expression cassette is selected from at least one of URA3 gene, LEU2 gene, TRP3 gene, HIS4 gene, ADE11 gene, LYS gene, argB gene, trpC gene, pyrG gene, or met3 gene expression cassette.
[0077] There are restriction sites and / or homologous sequences (Overhand sequences) between each element. For example, a homologous sequence is set between the promoter and the exogenous gene, a homologous sequence is set between the exogenous gene and the terminator, and a homologous sequence is set between the screening marker gene and the promoter. The length of the homologous sequence is 4 nucleotides.
[0078] For example, a homologous sequence of GCCT is set at the 5' end of the screening marker gene, a homologous sequence of ACGG is set between the screening marker gene and promoter 1, a homologous sequence of AATG is set between promoter 1 and exogenous gene 1, a homologous sequence of TCTA is set between exogenous gene 1 and terminator 1, a homologous sequence of GCTT is set between terminator 1 and promoter 2, a homologous sequence of ACAA is set between promoter 2 and exogenous gene 2, a homologous sequence of GGAT is set between exogenous gene 2 and terminator 2, a homologous sequence of GTCA is set between terminator 2 and promoter 3, a homologous sequence of CCAC is set between promoter 3 and exogenous gene 3, a homologous sequence of GTAT is set between exogenous gene 3 and terminator 3, and a homologous sequence of TGCG is set at the 3' end of terminator 3. In other embodiments, other homologous sequences with sequence consistency can also be set between adjacent elements, which are not limited to the nucleotide types of the above homologous sequences.
[0079] In a second aspect, the present invention further provides a recombinant cell or recombinant bacterium, which comprises the above-mentioned recombinant expression vector.
[0080] In a preferred embodiment of the present invention, the recombinant cell or recombinant bacteria is a bacterium or a fungus;
[0081] In a preferred embodiment of the present invention, the bacteria are Agrobacterium, Mycobacterium, Streptomyces, Escherichia coli or Bacillus subtilis;
[0082] In a preferred embodiment of the present invention, the fungus is Trichoderma reesei or yeast.
[0083] The host cells mentioned above include transformants and transformed cells, which include primary transformed cells and progeny derived therefrom, regardless of the number of passages. Progeny may not be completely identical to the parental cells in nucleic acid content, but may contain mutations.
[0084] Trichoderma reesei is a food-grade safety strain certified by the US FDA. As a production strain, this strain does not produce endotoxins similar to those produced by Escherichia coli. Compared with brewer's yeast fermentation, the fermentation process of Trichoderma reesei does not produce a large amount of heat, reducing the investment cost of cooling equipment. Compared with large fungi, the fermentation cycle of Trichoderma reesei is shorter.
[0085] In a preferred embodiment of the present invention, the yeast is selected from at least one of the following genera: Dekkera, Brettanomyces, Hansenula, Klebsiella, Pichia, Candida, Kluyveromyces, Debaryomyces, Kazachstania, Wickerhamomyces, Lindnera, Zygotorulaspora, Zygosaccharomyces, Rhodosporidium and Schizosaccharomyces;
[0086] In a preferred embodiment of the present invention, the yeast is Rhodosporidium toruloides.
[0087] The above-mentioned recombinant bacteria (or genetically engineered bacteria) are obtained by transforming the recombinant expression vector into a host microorganism by conventional methods in the art; the host microorganism can be any conventional host microorganism in the art, as long as the recombinant expression vector can stably replicate itself and the foreign gene carried can be effectively expressed. The host microorganism is a bacterium or a fungus.
[0088] In a preferred embodiment of the present invention, the recombinant bacteria refers to at least one of resting cells of the recombinant bacteria, living cells of the recombinant bacteria, dead cells of the recombinant bacteria, and cell fragments of the recombinant bacteria.
[0089] Dormant cells, also known as resting cells, are a special cell state. In this state, cells do not grow and reproduce, but still contain various enzyme systems and have oxidation and fermentation capabilities. Under suitable conditions, dormant cells can resume growth. The characteristics of dormant cells include: a. Cells maintain growth potential: Although in a dormant state, these cells can re-enter the cell cycle and restore their proliferation ability when given appropriate stimulation. b. Strong specificity: Dormant cells have strong specificity in the reaction and can improve the substrate conversion rate. c. Not easy to be contaminated by foreign bacteria: Due to its characteristics, dormant cells can reduce the inhibition of bacterial growth and enzyme synthesis by products during use.
[0090] Dead bacteria of recombinant bacteria include but are not limited to bacteria obtained by inactivation by heat, pressure, radiation, etc.
[0091] Cell disruption products refer to: including but not limited to, cell disruption products obtained by changing the permeability of cell membranes through ultrasonic, mechanical, chemical, biological and other means, resulting in leakage of cell contents.
[0092] In a preferred embodiment of the present invention, the dead bacteria are selected from at least one of a precipitate of dead bacteria and a cell-free supernatant of dead bacteria. The cell-free supernatant of dead bacteria refers to the "exudate contents" remaining after removing the outer shell of the dead bacteria.
[0093] In a third aspect, the present invention also provides a chassis Rhodosporidium toruloides cell capable of biosynthesizing exogenous active substances, which comprises the above-mentioned recombinant expression vector;
[0094] In a preferred embodiment of the present invention, the exogenous active substance is selected from fatty acids, exogenous terpenoid compounds, sugar alcohol compounds and polyketide compounds;
[0095] In a preferred embodiment of the present invention, the fatty acid is selected from a long-chain polyunsaturated fatty acid or a long-chain monounsaturated fatty acid;
[0096] In a preferred embodiment of the present invention, the long-chain polyunsaturated fatty acid is selected from C20 unsaturated fatty acid and C22 unsaturated fatty acid; the long-chain monounsaturated fatty acid is selected from palmitate, palmitoleic acid, 10E-heptadecenoic acid (C17:1n7, trans), 10Z-heptadecenoic acid (C17:1n7, cis), elaidic acid, octadecenoic acid, ricinoleic acid, oleic acid (C18:1n9), nonadecenoic acid (cis-10), 11Z-eicosenoic acid, erucic acid and C24 monounsaturated fatty acid;
[0097] In a preferred embodiment of the present invention, the C24 monounsaturated fatty acid is nervonic acid.
[0098] In a fourth aspect, the present invention also provides the use of a recombinant expression vector, a recombinant cell or a recombinant bacterium or the above-mentioned chassis Rhodosporidium toruloides cells in the synthesis of exogenous active substances.
[0099] In a preferred embodiment of the present invention, the exogenous active substance is selected from fatty acids, exogenous terpenoid compounds, sugar alcohol compounds and polyketide compounds.
[0100] In a fifth aspect, the present invention further provides a method for biosynthesizing an exogenous active substance, comprising the steps of any one of the following (1)-(2):
[0101] (1) transforming the above-mentioned recombinant expression vector into host cells and culturing the cells;
[0102] (2) culturing the above-mentioned recombinant cells or recombinant bacteria or the above-mentioned Rhodosporidium toruloides cells;
[0103] In a preferred embodiment of the present invention, in method (1), the recombinant expression vector is first transformed into Agrobacterium; and then the Agrobacterium is transformed into Rhodosporidium toruloides;
[0104] In a preferred embodiment of the present invention, the recombinant expression vector is first transformed into Escherichia coli, and the correctly sequenced recombinant expression vector is selected to transform Agrobacterium; and then the Agrobacterium is transformed into Rhodosporidium toruloides.
[0105] In an optional embodiment, the Rhodosporidium toruloides cells and / or culture medium containing the exogenous active substance are harvested; and the exogenous active substance is purified.
[0106] The separation and purification methods include, but are not limited to, salting out, ultrafiltration, affinity chromatography, gel filtration chromatography, and ion exchange columns.
[0107] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.
[0108] Example 1
[0109] The present embodiment takes the biosynthesis of nervonic acid in Rhodosporidium torophylla as an example, and provides an expression vector for recombinantly expressing 3-ketoacyl-CoA synthetase. The complete nervonic acid synthesis pathway usually requires three KCS (3-ketoacyl-CoA synthetase) key genes. KCS plays a very important role in the synthesis of very long-chain fatty acids such as plant nervonic acid. It is a key enzyme and a rate-limiting enzyme that can determine the substrate specificity and the carbon chain length of the product. It can form a complex with three other enzymes in the plant body or in the yeast body, catalyze and utilize C18:1 and above fatty acids, and through condensation, reduction, dehydration, and re-reduction four reactions, the carbon chain is extended by one 2C unit, and C18:1 can be converted into C24:1 (i.e. nervonic acid) through three continuous cycles.
[0110] The three KCS genes used in this example are all derived from plants. Gene 1 is CgKCS from Cardaminegraeca, gene 2 is AtKCS18 from Arabidopsis thaliana, and gene 3 is CraKCS from Crambe abyssinica. After optimizing the codon preference of Rhodosporidium toruloides, a recombinant expression vector containing neuraminic acid anabolism function was constructed using the RtGGA Assembly Platform.
[0111] The specific steps include:
[0112] 1. Composition and design of RtGGA Assembly Platform
[0113] According to the transformation method used, which is Agrobacterium-mediated transformation of Rhodosporidium toruloides, the elements of RtGGA Assembly Platform include: Promoter 1 / 2 / 3, Gene 1 / 2 / 3, Terminator 1 / 2 / 3, screening marker, and basic vector pZPK-AmpR-KanR-RFP. The foreign gene and screening marker gene are inserted between the two BsaI restriction sites of the basic vector pZPK-AmpR-KanR-RFP. The promoters Promoter 1 / 2 / 3 are all endogenous constitutive promoters in Rhodosporidium toruloides, namely: pPGI (glucose 6-phosphate isomerase), pGPD (3-phosphate glyceraldehyde dehydrogenase), pFBA (fructose 1,6-bisphosphate aldolase); the terminators Terminator 1 / 2 / 3 are: Thsp (endogenous heat shock protein), Tgpd (endogenous 3-phosphate glyceraldehyde dehydrogenase), T35S (exogenous cauliflower mosaic virus 35S gene); the genes Gene 1 / 2 / 3 are as described above.
[0114] The screening marker Marker includes four resistance screening markers and one nutritional deficiency screening marker, which can be selected as needed. In this embodiment, the resistance screening marker is selected from the hygromycin HYG expression cassette. In other embodiments, it can also be at least one of the following expression cassettes: bleomycin expression cassette, nourseoin expression cassette, geneticin expression cassette, and the nutritional deficiency screening marker is the URA3 expression cassette.
[0115] RtGGA Assembly Platform components and schematic diagram reference Figure 1 shown.
[0116] 2. Pre-construction of RtGGA Assembly Platform components
[0117] All components of the RtGGA Assembly Platform were constructed using homologous recombination. The components of the RtGGA Assembly Platform include: Promoter 1 / 2 / 3, Gene 1 / 2 / 3, Terminator 1 / 2 / 3, Screening Marker HYG (as shown in SEQ ID NO: 10), and the basic vector pZPK-AmpR-KanR-RFP. Promoter 1 / 2 / 3 specifically includes: glucose 6-phosphate isomerase promoter (PPGI), 3-phosphoglyceraldehyde dehydrogenase promoter (pGPD), fructose 1,6-bisphosphate aldolase promoter (pFBA), and their nucleotide sequences are shown in SEQ ID NO: 1-3. Gene 1 / 2 / 3 are CgKCS of Cardamine graeca, AtKCS18 of Arabidopsis thaliana and CraKCS of Crambe abyssinica, and the nucleotide sequences of CgKCS, AtKCS18 and CraKCS are shown in SEQ ID NOs: 4-6. Terminator 1 / 2 / 3 are CaMV35S terminator T35S, endogenous heat shock protein Thsp of Rhodosporidium toruloides and endogenous 3-phosphoglyceraldehyde dehydrogenase Tgpd of Rhodosporidium toruloides, and the nucleotide sequences of these are shown in SEQ ID NOs: 7-9.
[0118] (1) For Promoter 1 / 2 / 3, Terminator 1 / 2 / 3, and Screening Marker, primers are designed and then amplified with a high-fidelity enzyme so that the elements carry the corresponding BsaI restriction site sequence and the corresponding Overhand sequence, and then connected to the plasmid backbone by homologous recombination to construct an intermediate vector carrying the corresponding elements.
[0119] For Gene 1 / 2 / 3, they were optimized according to the codon preference of Rhodosporidium toroculans during gene synthesis, and the BsaI restriction site sequence and the corresponding Overhand sequence were added to the two ends of the gene according to the location of the gene placement (refer to Figure 1 As shown). Colony PCR was performed on the intermediate vectors carrying promoter 1 / 2 / 3, terminator 1 / 2 / 3, selection marker and other elements, and the results were referred to Figure 2 As shown, the results show that the band size is single and bright, and it is in line with expectations. The primer sequences for colony PCR are as follows (applicable to intermediate vectors carrying promoter 1 / 2 / 3, terminator 1 / 2 / 3, screening marker and other elements):
[0120] ori-seq-1:ACCTCTGACTTGAGCGTCGA;
[0121] ccdB-seq-1:CCTTAAACTGCCGTACGTAT.
[0122] (2) For the basic vector pZPK-AmpR-KanR-RFP (i.e. Fig. 9 The structure of the RtGGA final vector backbone double antibody pZPK-AmpR-KanR-RFP) in the PCR product consists of 4 parts:
[0123] ①pZPK backbone: It is an essential element for Agrobacterium and Escherichia coli expression. It was obtained by double digesting the pZPK-HYG-MCS plasmid (gifted by Professor Zhao Zongbao of Dalian University of Technology) with BspH1 and Pme1 to recover a 6085 bp fragment;
[0124] ②AmpR expression cassette: obtained by high-fidelity enzyme amplification using the final vector plasmid in the independently constructed YlGGA as a template (1034 bp, the AmpR expression cassette sequence is shown in SEQ ID NO.11);
[0125] ③ KanR expression cassette: The component plasmids other than the final vector in the independently constructed YlGGA were used as templates and amplified with high-fidelity enzymes (1191 bp, the sequence of KanR expression cassette is shown in SEQ ID NO.12);
[0126] ④RFP expression cassette: obtained by high-fidelity enzyme amplification using the final vector plasmid in the independently constructed YlGGA as a template (1180 bp, the RFP expression cassette sequence is shown in SEQ ID NO.13);
[0127] ⑤ Then, the pZPK backbone, AmpR expression cassette, KanR expression cassette and RFP expression cassette were homologously recombined to construct the RtGGA basic vector pZPK-AmpR-KanR-RFP ( Fig. 9 shown).
[0128] Colony PCR primers:
[0129] RepA-seq-1AGATCGTAAAGAGCGAAACC;
[0130] Amp-R ATAATACCGCGCCACATAGC.
[0131] The results of colony PCR of the final vector pZPK-Ampr-Kanr-RFP are as follows Figure 3 Shown: The band size is uniform and bright, and is consistent with expectations.
[0132] The final vector was digested with restriction enzyme BsaI. The correct band should be 1099bp+6682bp. The digestion result is as follows: Figure 4 Shown: The bands were consistent with expectations, indicating that the final vector was correct.
[0133] 3. Construction of RtGGA Assembly Platform (recombinant expression vector)
[0134] Construction of recombinant expression vector: The E. coli strain containing the final vector pZPK-Ampr-Kanr-RFP was cultured in LB liquid medium containing ampicillin (50 μg / mL) and kanamycin (25 μg / mL), and the E. coli strain containing promoter Promoter 1 / 2 / 3, gene Gene 1 / 2 / 3, terminator Terminator 1 / 2 / 3 and selection marker was cultured in LB liquid medium containing kanamycin (50 μg / mL), and the plasmid was extracted and the plasmid concentration was measured. Then the system was configured according to the following Table 1:
[0135] Table 1 Construction system of recombinant expression vector
[0136]
[0137] After the system is prepared, set the program in Table 2 in the PCR instrument to perform Golden Gate cloning assembly:
[0138] Table 2 PCR program
[0139]
[0140] After the Golden Gate clone assembly is completed, E. coli DH5α is transformed, and the resistance screening plate used contains ampicillin (50μg / mL) and kanamycin (25μg / mL). Since the final vector contains a red fluorescent protein expression cassette, the colonies of the uninserted fragments, i.e., empty transformants, will appear red after being placed in the refrigerator for 1 day. After the Golden Gate clone assembly, the inserted fragments will replace the red fluorescent protein expression cassette, so that the colonies of the positive clones generally appear as ordinary E. coli colonies, i.e., milky white, without showing red. Therefore, after the transformants grow on the screening plate, they can be placed in the refrigerator for a period of time, and then the milky white colonies are picked for 3 colony PCR verifications to identify the presence of the three genes, and sequenced. The plasmids with correct sequencing will be used for subsequent Agrobacterium transformation.
[0141] Through the RtGGA Assembly Platform, the expression cassettes consisting of three KCS genes from different plant sources (pPGI-CgKCS-Thsp, pGPD-AtKCS18-Tgpd, pFBA-CraKCS-T35) were successfully constructed into a recombinant expression vector (RtGGA-3KCS vector) using the Golden Gate cloning assembly method. After transformation into DH5a, the transformants were verified by colony PCR. The results were referenced Figure 5 As shown: After sequencing, the PCR band size was consistent with expectations, the sequencing results were consistent with the original sequence, and the transformant colonies were white, indicating that the recombinant expression vector was successfully constructed.
[0142] The primers used for colony PCR were:
[0143] kan-seq-5:AATCAACATGCTACCCTCCG;
[0144] PGI-seq-3: CAATCAACACCTTCTGACCC.
[0145] Example 2
[0146] The recombinant expression vector was transformed into competent Agrobacterium.
[0147] The transformation method of Agrobacterium AGL1 is as follows: ① Take the competent cells of Agrobacterium AGL1 out of the -80℃ refrigerator, hold them lightly in the center of your fingers for a while, and then place them on ice to melt. ② After the competent cells of AGL1 melt, add the above-mentioned approximately 600ng of the verified plasmid to the competent cells of AGL1, and flick the tube wall to mix the plasmid and competent cells evenly. ③ Place the mixture of the plasmid and competent cells on ice for 5 minutes, freeze them in liquid nitrogen for 5 minutes, and heat shock them in a 37℃ water bath for 5 minutes. ④ After the transformation is completed, add 600μL of antibiotic-free LB liquid culture medium and place it in a 28℃ shaker for 3h. ⑤ Take about 200μL of the culture solution and apply it to the LB plate culture medium containing kanamycin (50μg / mL) and rifampicin (20μg / mL), dry it, and culture it at 28℃ for 2-3 days. ⑥ After the transformants grow on the plate, pick a single clone as a template, perform colony PCR verification and streak it onto an LB plate containing kanamycin (50 μg / mL) and rifampicin (20 μg / mL), and culture it at 28°C for 1 day. The correct Agrobacterium verified by colony PCR will be used for subsequent Rhodosporidium toruloides transformation.
[0148] Randomly pick Agrobacterium single clones for colony PCR verification, and refer to Figure 6 As shown: The PCR band size was consistent with the expected value, indicating that the recombinant vector was successfully transformed into Agrobacterium AGL1.
[0149] Example 3
[0150] Agrobacterium was co-cultivated with Rhodosporidium toruloides.
[0151] (1) Preparation of Agrobacterium carrying expression vector: ① Initial activation: Pick the Agrobacterium strain that has been transferred with the target plasmid and inoculate it into a 5 mL sterile centrifuge tube containing 2 mL LB liquid culture medium (with rifampicin and kanamycin). Shake the bacteria overnight at 28°C and 220 rpm in a shaker. ② Secondary activation: Take 1 mL of the initial activation solution and inoculate it into a 50 mL sterile centrifuge tube containing 5 mL LB liquid culture medium (containing rifampicin + corresponding antibiotics), and culture it overnight at 28°C for about 14-16 hours. Measure the OD600 value, calculate the dilution multiple, wash the bacteria twice with sterile water (4000 rpm, 5 min), and dilute with sterile water to OD600 = 0.6-0.8.
[0152] (2) Preparation of Rhodosporidium torophyllum NP11: ① Initial activation: Pick the Rhodosporidium torophyllum NP11 strain and inoculate it into a 5 mL sterile centrifuge tube containing 2 mL YPD liquid medium. Shake the culture overnight at 28°C and 220 rpm. ② Secondary activation: Take 1 mL of the initial activation solution and inoculate it into a 50 mL sterile centrifuge tube containing 5 mL YPD liquid medium, and culture it overnight at 28°C for about 14-16 hours. Measure the OD600 value, calculate the dilution multiple, wash the cells twice with sterile water (4000 rpm, 5 min), and dilute with sterile water to OD600 = 0.6-0.8.
[0153] (3) Induction culture: Take 100 μL of each of the diluted Agrobacterium and Rhodosporidium toruloides suspensions, mix them, and spot them on an IM plate with sterile filter paper (or directly apply them on the IM plate). Place the plate with the front side facing up in a 25°C incubator and culture it. After 2-3 days of culture, a slightly reddish bacterial moss can be seen growing on the plate.
[0154] (4) Screening culture: Wash the bacterial moss on the filter paper with sterile water (or directly scrape the bacterial moss), spread it on the corresponding solid resistance screening medium plate, and culture it at 28°C. Single colonies can be seen after about 2-3 days. Since Agrobacterium can also grow on YPD-HYG solid medium plates, it is difficult to distinguish whether the newly grown colonies are Agrobacterium or successfully transformed Rhodosporidium toruloides. The plate with a single colony can be placed in a 4°C refrigerator for 1-2 days. When the Rhodosporidium toruloides turns pink, pick the pink single colony for phenotypic and genotypic verification.
[0155] Extract the genome and perform genomic PCR to detect gene insertion. The method for extracting the genome is as follows:
[0156] The yeast transformant to be verified was placed in a 1.5 mL sterile centrifuge tube containing 700 μL YPD liquid medium, shaken and cultured overnight at 28°C 220 rpm until turbid, centrifuged at 12000 rpm for 5 min, and the supernatant was removed; 100 μL of 0.2 M lithium acetate solution and 100 μL of 1% SDS solution were added, shaken evenly, and placed in a 70°C metal bath for 10 min; after the metal bath was cooled, 300 μL of anhydrous ethanol was added, centrifuged at 12000 rpm for 3 min, and the supernatant was removed; 300 μL of 70% ethanol was added, shaken and resuspended, centrifuged at 12000 rpm for 3 min, the supernatant was removed and the residual ethanol was blown dry; 50 μL of deionized water was added, shaken, and fully re-dissolved; 12000 rpm, centrifuged for 5 min, and 2 μL of supernatant was taken as a template for genomic PCR verification.
[0157] Then the three exogenous genes were detected. The colony PCR primers of the target genome are as follows:
[0158] Gene 1: amplified fragment length 1549 bp;
[0159] RtGGA-3KCS-test1F CGCTACGAACCAATGATGAC;
[0160] RtGGA-3KCS-test3 CGGAATCGTTAGACTACGAG.
[0161] Gene 2: amplified fragment length 1543 bp;
[0162] RtGGA-3KCS-test2F GTCACAACAAATGACCTCGG;
[0163] RtGGA-3KCS-test1RgaaaccgcATCCCTACGAGC;
[0164] Gene 3: amplified fragment length 1549 bp;
[0165] RtGGA-3KCS-test4 CTAGCTACACCACATGACCTC;
[0166] RtGGA-3KCS-test2R GATTTCAGCGTATACCTACGAG.
[0167] Genomic PCR results reference Figure 7 As shown: The PCR band sizes were consistent with expectations, indicating that the three exogenous genes were integrated into the NP11 genome.
[0168] Example 4
[0169] Detection of RtGGA Assembly Platform platform functions.
[0170] (1) Phenotypic identification: After transformants grow on the screening plate and develop color, pick the pink single clone and place it in a solid culture medium with the corresponding resistance screening marker or nutritional deficiency marker, culture it at 28°C, and observe its growth status on the plate. If the growth status is good and it is placed in the refrigerator for 1-2 days, it will gradually turn pink.
[0171] (2) Product identification: After fermentation, the product is detected according to the corresponding method.
[0172] The fatty acid composition of the recombinant strain NP11-3KCS was determined by gas chromatography.
[0173] Gas chromatography method for detecting fatty acids:
[0174] (1) Sample pretreatment: After fermentation, collect 10 mL of bacterial solution, centrifuge at 4000 rpm for 10 min, discard the supernatant, collect the bacterial cells and prefreeze them in a -80°C refrigerator for more than 2 h, and then freeze-dry them in a vacuum freeze dryer for 72 h; grind the freeze-dried samples into bacterial powder.
[0175] (2) Methylation: Weigh 10 mg of bacterial powder and place it in a 4 mL threaded transparent glass bottle. Add 40 μL of 1 mg / mL heneicosanoic acid methyl ester (C21:0) standard as the internal standard for quantitative analysis of fatty acids and 750 μL of methanolic sulfuric acid (methanol: sulfuric acid = 95:5) (volume ratio) to generate fatty acid methyl esters. Oscillate with a vortex oscillator for 3 min until no larger particles are visible. Then place the mixed sample in a 90°C metal bath for 90 min.
[0176] (3) Extraction of fatty acids: After the sample has cooled, add 500 μL of saline and 300 μL of n-hexane, and vortex again for about 3 min to mix. Then, centrifuge at 3000 rpm at room temperature for 10 min. Take the upper layer of liquid into a 1.5 mL centrifuge tube and centrifuge at 12000 rpm for 5 min. Take 200 μL of the supernatant (do not take the lower layer of liquid) and add it to the gas phase bottle containing the liner tube.
[0177] (4) Detection of fatty acids: Agilent 7890A gas chromatograph (GC) was used to analyze and detect the prepared fatty acid methyl ester samples. The chromatographic column used for analysis was HP-FFAP type, with specifications of 30mm×250μm×0.25μm. The detector type was a hydrogen ion flame detector (FID). Heating program: initial temperature, 150℃, 10℃ / min to 210℃, hold for 7min, continue to heat to 230℃ at 20℃ / min, hold for 6min; split ratio: 30:1; injection port temperature was 260℃.
[0178] The results showed that the fatty acid composition of the recombinant strain NP11-3KCS was significantly changed compared with NP11 ( Figure 8 ), firstly, the peaks of the target product C24:1 (about 2.00%) and the intermediate products C20:1 (about 6.26%) and C22:1 (4.05%) appeared, as well as a small amount of C22:0 (0.30%), and the content of C24:0 also increased (from 0.85% to 1.20%). This shows that these exogenous KCS were successfully integrated into the genome of Rhodosporidium toruloides and played a corresponding role under the drive of the promoter, successfully constructing the heterologous biosynthesis pathway of neuraminic acid in Rhodosporidium toruloides.
[0179] In summary, the present invention designs and develops a new genetic transformation operation tool RtGGA Assembly Platform based on the unique transformation method of Rhodosporidium toruloides (Agrobacterium-mediated transformation), which includes 3 different promoters, 3 different terminators, 5 different screening markers and a final vector; it can realize the random integration and expression of three genes at one time and perform 5 rounds of gene expression integration.
[0180] The present invention takes the construction of the nervonic acid anabolic pathway as an example, and by using the genetic manipulation tool RtGGA Assembly Platform designed and developed in this study, three exogenous fatty acid elongase genes CgKCS, AtKCS18 and CraKCS were cloned into the pZPK-Ampr-Kanr-RFP vector at one time, and transformed into Rhodosporidium toruloides by Agrobacterium-mediated transformation, and successfully constructed the nervonic acid anabolic pathway in Rhodosporidium toruloides, and the relative content of nervonic acid in the total fatty acids of the recombinant yeast was 2%, indicating the feasibility and efficiency of the RtGGA Assembly Platform.
[0181] The establishment of the RtGGA Assembly Platform simplifies and accelerates the integration and expression process of multiple genes in Rhodosporidium toruloides, and establishes an efficient, flexible, standardized and modular synthetic biology platform. It is expected to promote the development of the field of synthetic biology of Rhodosporidium toruloides and promote the widespread application of Rhodosporidium toruloides in biomanufacturing, bioenergy and biomedicine.
[0182] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. A recombinant expression vector, characterized in that: The recombinant expression vector comprises a basic vector, and the following elements on the basic vector: a promoter, a foreign gene, a terminator and a selection marker gene; the promoter is an endogenous constitutive promoter in Rhodosporidium toruloides; The basic vector also includes a pZPK skeleton, a bacterial selection marker expression cassette and a fungal selection marker expression cassette; and the number of the exogenous genes is at least 2.
2. The recombinant expression vector according to claim 1, characterized in that The endogenous constitutive promoter in the Rhodosporidium toruloides yeast is selected from at least one of a glucose 6-phosphate isomerase promoter, a 3-phosphoglyceraldehyde dehydrogenase promoter, a fructose 1,6-bisphosphate aldolase promoter, a glyceraldehyde phosphate dehydrogenase promoter, a translation elongation factor promoter, and a promoter of Pichia pastoris enolase 1, a triosephosphate isomerase, a ribosomal subunit protein, an alcohol oxidase promoter or a variant with modified characteristics, a formaldehyde dehydrogenase promoter, an isocitrate lyase promoter, an α-ketoisocaproate decarboxylase promoter, a heat shock protein family member promoter, a 6-phosphogluconate dehydrogenase promoter, a phosphoglycerate mutant enzyme promoter, a transketolase promoter, and a phosphatidylinositol synthase promoter; Preferably, the endogenous constitutive promoter in Rhodosporidium toruloides is selected from at least one of a glucose 6-phosphate isomerase promoter, a 3-phosphate glyceraldehyde dehydrogenase promoter and a fructose 1,6-bisphosphate aldolase promoter; Preferably, the nucleotide sequences of the glucose 6-phosphate isomerase promoter, the glyceraldehyde-3-phosphate dehydrogenase promoter and the fructose 1,6-bisphosphate aldolase promoter are shown in SEQ ID NOs: 1-3, respectively.
3. The recombinant expression vector according to claim 1, characterized in that The exogenous gene is selected from genes used to express exogenous peptides or exogenous proteins; Preferably, the exogenous peptide or exogenous protein is selected from enzymes in fatty acid synthesis, enzymes in exogenous terpenoid synthesis, enzymes in sugar alcohol synthesis, and enzymes in polyketide synthesis; Preferably, the fatty acid is selected from the group consisting of long-chain polyunsaturated fatty acids, long-chain monounsaturated fatty acids, long-chain saturated fatty acids, medium-chain fatty acids and short-chain fatty acids; Preferably, the long-chain polyunsaturated fatty acids are selected from eicosapentaenoic acid (EPA, C20:5n3), α-linolenic acid (ALA, C18:3n3), γ-linolenic acid (C18:3n6), linoleic acid (C18:2n6, allcis), linolenic acid (C18:2n6, alltrans), conjugated linoleic acid (CLA, C18:2), myristoleic acid, 10,13-nonadecadienoic acid, cis- cis-11,14,17-eicosatrienoic acid (C20:3n3), cis-8,11,14-eicosatrienoic acid methyl ester (C20:3n6), arachidonic acid (C20:4n6), 13Z,16Z-docosadienoic acid (C22:2n6), docosatetraenoic acid (C22:4n6), docosapentaenoic acid (C22:5n6) and docosahexaenoic acid (DHA, C22:6n3); The long-chain monounsaturated fatty acid is selected from palmitate, palmitoleic acid, 10E-heptadecenoic acid (C17:1n7, trans), 10Z-heptadecenoic acid (C17:1n7, cis), elaidic acid, octadecenoic acid, ricinoleic acid, oleic acid (C18:1n9), nonadecenoic acid (cis-10), 11Z-eicosenoic acid, erucic acid and C24 monounsaturated fatty acid; Preferably, the C24 monounsaturated fatty acid is nervonic acid; Preferably, the enzyme in fatty acid synthesis is selected from 3-ketoacyl-CoA synthetase; Preferably, the exogenous gene is selected from at least one of CgKCS of Cardamine graeca, AtKCS18 of Arabidopsis thaliana and CraKCS of Crambe abyssinica; Preferably, the nucleotide sequences of CgKCS, AtKCS18 and CraKCS are shown in SEQ ID NO: 4-6; Preferably, the terminator is selected from at least one of the terminator nosT of the nopaline synthase gene of Agrobacterium tumefaciens, the terminator T35S of CaMV35S, the endogenous heat shock protein Thsp of Rhodosporidium toruloides and the endogenous 3-phosphoglyceraldehyde dehydrogenase Tgpd of Rhodosporidium toruloides; Preferably, the nucleotide sequences of the CaMV35S terminator T35S, the Rhodosporidium toruloides endogenous heat shock protein Thsp and the Rhodosporidium toruloides endogenous 3-phosphoglyceraldehyde dehydrogenase Tgpd are shown in SEQ ID NOs: 7-9, respectively; Preferably, when there are multiple foreign genes, the elements on the basic vector include: promoter-foreign gene 1-terminator-promoter-foreign gene 2-terminator-…foreign gene n-terminator-selection marker gene; Or, screening marker gene-promoter-foreign gene 1-terminator-promoter-foreign gene 2-terminator-…foreign gene n-terminator; n≥2.
4. The recombinant expression vector according to claim 1, characterized in that The selection marker gene is selected from at least one of bleomycin, geneticin, hygromycin, nourseoin, xanthine / guanine phosphotransferase gene (gpt), hypoxanthine phosphotransferase gene (Hprt), thymidine kinase gene (tk), puromycin acetyltransferase gene (puro), and auxotrophic marker genes; The auxotrophic marker gene is selected from at least one of the URA3 gene, the LEU2 gene, the TRP3 gene, the HIS4 gene, the ADE11 gene, the LYS gene, the argB gene, the trpC gene, the pyrG gene, or the met3 gene; Preferably, the bacterial selection marker expression cassette is selected from AmpR expression cassette, KanR expression cassette, tetracycline resistance gene (tetR) expression cassette, spectinomycin resistance gene expression cassette, chloramphenicol resistance gene (cat) expression cassette, RFP expression cassette and hygromycin resistance gene (hpt), and the fungal selection marker expression cassette is selected from resistance selection marker expression cassette and / or nutrient deficiency marker expression cassette; the resistance selection marker expression cassette is selected from: geneticin resistance gene expression cassette, bleomycin resistance gene expression cassette, nourseoin resistance gene expression cassette or hygromycin resistance gene (hpt); the nutrient deficiency marker expression cassette is selected from at least one of URA3 gene, LEU2 gene, TRP3 gene, HIS4 gene, ADE11 gene, LYS gene, argB gene, trpC gene, pyrG gene, or met3 gene expression cassette; Preferably, there are restriction sites and / or homologous sequences between each of the elements.
5. A recombinant cell or recombinant bacterium, characterized in that: It comprises the recombinant expression vector according to any one of claims 1 to 4.
6. The recombinant cell or recombinant bacterium according to claim 5, characterized in that: The recombinant cell or recombinant bacteria is a bacterium or a fungus; Preferably, the bacterium is Agrobacterium, Mycobacterium, Streptomyces, Escherichia coli or Bacillus subtilis; Preferably, the fungus is Trichoderma reesei or yeast; Preferably, the yeast is selected from at least one of the following genera: Dekkera, Brettanomyces, Hansenula, Kluyveromyces, Pichia, Candida, Kluyveromyces, Debaryomyces, Kazachstania, Wickerhamomyces, Lindnera, Zygotorulaspora, Zygosaccharomyces, Rhodosporidium and Schizosaccharomyces; Preferably, the yeast is Rhodosporidium toruloides.
7. A Rhodosporidium toruloides cell capable of biosynthesizing exogenous active substances, characterized in that: It comprises the recombinant expression vector according to any one of claims 1 to 4; Preferably, the exogenous active substance is selected from fatty acids, exogenous terpenoid compounds, sugar alcohol compounds and polyketide compounds; Preferably, the fatty acid is selected from long-chain polyunsaturated fatty acids or long-chain monounsaturated fatty acids; Preferably, the long-chain polyunsaturated fatty acid is selected from C20 unsaturated fatty acid and C22 unsaturated fatty acid; the long-chain monounsaturated fatty acid is selected from palmitate, palmitoleic acid, 10E-heptadecenoic acid (C17:1n7, trans), 10Z-heptadecenoic acid (C17:1n7, cis), elaidic acid, octadecenoic acid, ricinoleic acid, oleic acid (C18:1n9), nonadecenoic acid (cis-10), 11Z-eicosenoic acid, erucic acid and C24 monounsaturated fatty acid; Preferably, the C24 monounsaturated fatty acid is nervonic acid.
8. Use of the recombinant expression vector according to any one of claims 1 to 4, the recombinant cell or recombinant bacterium according to any one of claims 5 to 6, or the Rhodosporidium toruloides cell according to claim 7 in the synthesis of exogenous active substances.
9. The use according to claim 8, characterized in that: The exogenous active substances are selected from fatty acids, exogenous terpenoid compounds, sugar alcohol compounds and polyketide compounds.
10. A method for biosynthesis of exogenous active substances, characterized in that: It includes the steps described in any one of the following (1)-(2): (1) transforming host cells with the recombinant expression vector according to any one of claims 1 to 4, and culturing the cells; (2) culturing the recombinant cell or recombinant bacterium according to any one of claims 5 to 6 or the Rhodosporidium toruloides cell according to claim 7; Preferably, in the method (1), the recombinant expression vector is first transformed into Agrobacterium; and then the Agrobacterium is transformed into Rhodosporidium toruloides; Preferably, the recombinant expression vector is first transformed into Escherichia coli, and the recombinant expression vector with correct sequencing is selected to transform Agrobacterium; and then the Agrobacterium is transformed into Rhodosporidium toruloides.
Citation Information
Cited By
RcICL promoter deletion fragment and application thereof
CN122445639A
